source
- Novo Nordisk seeks injunction to halt Eli Lilly's obesity drug adsNovo Nordisk filed a motion in a New Jersey federal court asking for a preliminary injunction that would stop Eli Lilly's advertisements for its obesity treatments. Novo claims the ads are mislead…
- Scribe Therapeutics raises $129 million in gene-editing IPO, debuting on NasdaqScribe Therapeutics completed an initial public offering that raised close to $129 million. The company sold 8.58 million shares at $15 each and will trade on Nasdaq under the ticker SCTX. The off…